Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Elubrixin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 known ✓ | P25025 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elubrixin SCHEMBL30515706 | 1.00 | CXCR2 (1.00) | CXCR2 | |
| Elubrixin SCHEMBL1741720 | 0.99 | CXCR2 (0.98) | CXCR2 | |
| Elubrixin SCHEMBL1663270 | 0.91 | CXCR2 (0.83) | CXCR2 | |
| SCHEMBL6564144 | 0.91 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL1562925 | 0.88 | CXCR2 (1.00) | CXCR2 | |
| Hydrochloric Acid SCHEMBL4355911 | 0.87 | CXCR2 (0.98) | CXCR2 | |
| Trifluoroacetic Acid SCHEMBL4588697 | 0.86 | CXCR2 (0.87) | CXCR2 | |
| SCHEMBL335883 | 0.85 | CXCR2 (0.74) | CXCR2 | |
| SCHEMBL334857 | 0.85 | CXCR2 (0.73) | CXCR2 | |
| SCHEMBL1562889 | 0.84 | CXCR2 (0.81) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099526-A1 | COMBINATION OF INHIBITORS OF IL-1BETA, CCR5 OR CXCR2 CYTOKINE RECEPTORS FOR USE IN THE TREATMENT OF METASTASIS | FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (ES) | 2026-05-15 | — | — | WO | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2025151629-A2 | METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH INFLAMMATION, PAIN AND/OR LESIONS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2024026528-A1 | DOSAGE REGIMEN FOR THE TREATMENT OF COPD | DIMERIX BIOSCIENCE PTY LTD (AU) | 2024-02-08 | — | — | WO | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230310479-A1 | LOW DOSE ADJUVANT EPIGENETIC CANCER THERAPY | UNIV JOHNS HOPKINS (US) | 2023-10-05 | — | — | US | claimed |
| EP-3554541-B1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A CHEMOKINE/CHEMOKINE RECEPTOR INHIBITOR | BIORA THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | claimed |
| US-11603569-B2 | Immune modulating genes for prognosis, diagnosis and treatment of metastatic disease, and drug identification methods thereof | CEDARS-SINAI MEDICAL CENTER (US) | 2023-03-14 | — | — | US | claimed |
| EP-4140486-A1 | METHODS AND COMPOUNDS FOR THE ALLEVIATION AND/OR PREVENTION OF PAIN | Klareskog, Lars (SE) | 2023-03-01 | — | — | EP | claimed |
| EP-3316886-B1 | METHODS AND COMPOUNDS FOR THE ALLEVIATION AND/OR PREVENTION OF PAIN | SVENSSON CAMILLA (SE) | 2022-05-18 | — | — | EP | claimed |
| US-20090281110-A1 | Method of Treatment | SMITHKLINE BEECHAM CORPORATION | 2009-11-12 | — | — | US | claimed |
| EP-2032131-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2009-09-02 | — | — | EP | claimed |
| US-20090093492-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION | 2009-04-09 | — | — | US | claimed |
| EP-1558259-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2009039091-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-26 | — | — | WO | claimed |
| EP-2032131-A2 | METHOD OF TREATMENT | SmithKline Beecham Corporation (US) | 2009-03-11 | — | — | EP | claimed |
| WO-2007150015-A2 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-27 | — | — | WO | claimed |
| US-20060040952-A1 | Il-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-23 | — | — | US | claimed |
| EP-1558259-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-03 | — | — | EP | claimed |
| WO-2004039775-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040952-A1 | Il-8 receptor antagonists | CXCL8, CCR8, IL1RN | CXCR2 9/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | CXCR2 1756/4885 |
| US-20090093492-A1 | IL-8 RECEPTOR ANTAGONISTS | CXCL8, CCR8, IL1RN | CXCR2 9/4885 |
| US-20090281110-A1 | Method of Treatment | ESR2, CTH, SULT2A1 | CXCR2 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.